HIV Prevention Drug Lenacapavir Could Cost $25 Per Year Under New Pricing Plan
A new HIV prevention drug called lenacapavir could be sold for as little as $25 per patient per year through subscription pricing models. The twice-yearly injection provides nearly total protection against HIV infection.
Lenacapavir, a breakthrough HIV prevention medication, could be mass-produced and sold for as low as $25 per patient per year, according to new research presented at IDWeek 2025. The drug is given as an injection just twice per year and provides nearly complete protection against HIV infection.
Health experts are pushing for subscription-based pricing models, similar to Netflix, where health systems would pay a flat fee to provide the medication to as many patients as needed. This approach could maximize access while controlling costs for healthcare systems.
The Gates Foundation has partnered with an Indian manufacturer to create low-cost generic versions of lenacapavir for low- and middle-income countries. This partnership aims to make the medication available to millions more people at risk of HIV infection.
Current HIV prevention drugs are often too expensive for many patients and health systems. The new pricing models could remove these barriers and make ending the HIV epidemic achievable for the first time.
This could make HIV prevention affordable for millions of people worldwide who can't access current expensive treatments. The drug could help end the HIV epidemic if pricing barriers are removed.
Watch for approval of generic versions and implementation of subscription pricing models in different countries.
Was this article helpful?
0 people found this helpful